Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk"
Research output: Contribution to journal › Journal article › Research › peer-review
Recent primary prevention guidelines issued in Canada endorse the use of statin therapy among individuals at "intermediate risk" who have elevated levels of high-sensitivity C-reactive protein (hsCRP). However, trial data directly addressing whether this recommendation defines a patient population in which statin therapy is effective have not previously been published.
| Original language | English |
|---|---|
| Journal | Circulation. Cardiovascular Quality and Outcomes |
| Volume | 3 |
| Issue number | 5 |
| Pages (from-to) | 447-52 |
| Number of pages | 6 |
| DOIs | |
| Publication status | Published - Sep 2010 |
ID: 34154666